ScoreComparison
Why is Sonnet BioTherapeutics Holdings, Inc. ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -47.90% and Operating profit at -12.93% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -16.47
2
Flat results in Jun 25
- DEBT-EQUITY RATIO (HY) Highest at 8.29 %
- PRE-TAX PROFIT(Q) Lowest at USD -3.78 MM
- NET PROFIT(Q) Lowest at USD -3.78 MM
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 49.10%, its profits have fallen by -60.7%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Sonnet BioTherapeutics Holdings, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Sonnet BioTherapeutics Holdings, Inc.
-51.72%
-0.25
293.71%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-47.90%
EBIT Growth (5y)
-12.93%
EBIT to Interest (avg)
-16.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.97
Sales to Capital Employed (avg)
0.09
Tax Ratio
1.21%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.49%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.96
EV to EBIT
-0.14
EV to EBITDA
-0.15
EV to Capital Employed
-1.52
EV to Sales
1.99
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1327.40%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
NET PROFIT(HY)
Higher at USD -7.27 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
NET SALES(9M)
Higher at USD 1 MM
-11What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at 8.29 %
PRE-TAX PROFIT(Q)
Lowest at USD -3.78 MM
NET PROFIT(Q)
Lowest at USD -3.78 MM
Here's what is working for Sonnet BioTherapeutics Holdings, Inc.
Net Sales
At USD 1 MM has Grown at 5,268.84%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Sales
Higher at USD 1 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Sonnet BioTherapeutics Holdings, Inc.
Pre-Tax Profit
Lowest at USD -3.78 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -3.78 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Debt-Equity Ratio
Highest at 8.29 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
